My Son has Fetal Valproate Syndrome a type of Fetal Anti Convulsant Syndrome (FACS) caused by Sodium valproate (Epilim, Depakote, Depakene) that I took while pregnant to control epilepsy. Despite the 40% risk of birth defects the UK medicine regulator (MHRA) is refusing to issue warnings. A group of people affected by the harmful side effects of pharmaceutical products held a peaceful protest on 2nd August 2013 at the MHRA Headquarters in London. http:// is linking people affected by all medications to build up a global campaign to raise awareness of poor medicine regulation. I have put a link to this page on the front page of the website. If you would like to get involved in our global campaign please email me and join the public facebook group (Fetal AntiConvulsant Trust) to discuss strategy and the development of the campaign. I look forward to hearing from you. thank you. emma friedmann
Myopathies in systemic disease results from several different disease processes including endocrine, inflammatory, paraneoplastic, infectious, drug- and toxin-induced, critical illness myopathy, metabolic, collagen related,  and myopathies with other systemic disorders. Patients with systemic myopathies often present acutely or sub acutely. On the other hand, familial myopathies or dystrophies generally present in a chronic fashion with exceptions of metabolic myopathies where symptoms on occasion can be precipitated acutely. Most of the inflammatory myopathies can have a chance association with malignant lesions; the incidence appears to be specifically increased only in patients with dermatomyositis. 
Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to Advair Diskus. Prednisone reduction can be accomplished by reducing the daily prednisone dose by mg on a weekly basis during therapy with Advair Diskus. Lung function (mean forced expiratory volume in 1 second [FEV 1 ] or morning peak expiratory flow [AM PEF]), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition, patients should be observed for signs and symptoms of adrenal insufficiency, such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.